Back to EZorb Newsletter Index

EZorb

  

EZORB MONTHLY NEWSLETTER FEB 28, 2018

In this issue:

 

1. Share Success: Letters From Readers
2. Research News: Statin Eligibility Associated With Higher Cancer Risk
3. Useful Links
4. Calcium Absorption Test
5. What Are Others Saying About EZorb and Marvlix?
  

1. Share Success: Letters From Readers 


Letter I: From Wayne F., Missouri

Received at Testimonial Submit Form Thursday, January 25, 2018 at 11:38:03

(Unedited)

 

Hi, my name is Wayne F, from Missouri, 62 years old and in very good physical condition.

Around Christmas time I started to get some nerve pain in my arm and tightness or pressure feeling in my shoulder blade area. It increased nearly everyday until I was in constant pain, that was just two weeks after the holidays 2018.

I knew this feeling well because 12 years ago. I had neck surgery for it, it was exactly the same thing that the surgeon removed a bad bone spur and fused three vertebrae in my neck together for.

He told me the bone spur could come back and he was right.

I have since found this product online and now in just 10 days of using Ezorb I haven't had any pain for the last 5 days.

I know full well it is because of this product. I was dreading going to my doctor because I knew exactly what was going to have to happen again, another surgery, it was the only thing that worked back then.

I will continue to use Ezorb for as long as I have to. I know there are many other people who have what I have so give this stuff a try.

Thank you so much for publishing this information, I am very grateful.


Letter II: From Paul

Received at Testimonial Submit Form Sunday, October 01, 2017 at 23:05:24

(Unedited)

 

Hi, my name is Paul and I have ordered EZORB for my fiancé Christine. Christine had gone to a foot doctor due to pain in the bottom of her feet.

The doctor took x-rays of her feet and told her that she had heel spurs. He then proceeded to tell her that if they got worse - she would need surgery.

She didn't want any kind of surgery on her feet so she came home and did some online searches and found EZORB; read the reviews and decided to order it to try.

Well six months later, Christine went back to the same foot doctor and he took more x-rays to see how much worse her feet were. When he saw the x-rays, he came back into the room and told her - "there must be some mistake here. I must have the wrong x-rays because I don't see any heel spurs in these x-rays. Did you have surgery? If so, you had a good surgeon because I don't see any scars on the bottom of your feet."

That is when Christine told him about EZORB and that she started to feel a difference after the first three months of using it. The doctor then told her "I need to write this down and recommend it to my patients who want to avoid surgery!"


***************************************************

From the Desk of EZorb Newsletter Editor:

 
This newsletter is now read by over 95,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's quality of life. Your continuous support will be greatly appreciated by tens of thousands who have been suffering and would continuously suffer, without your help! Please email your story to sharesuccess @ ezorbonline.com or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public. If your testimonial is selected for publication, you will receive a gift to show our appreciation of your effort.


2. Research News: Statin Eligibility Associated With Higher Cancer Risk

 

Individuals eligible for statins according to the 2013 American College of Cardiology/American Heart Association (ACA/AHA) guidelines have a significantly increased risk for developing or dying of cancer compared with noneligible individuals, US researchers report.

Amit Pursnani (Northshore University Health System, Evanston, Illinois) and study co-authors say their findings suggest that "shared risk profiles and potential benefits of statins between cancer and cardiovascular outcomes may provide a unique opportunity to improve population health."

They report that, at a median 10 years of follow-up, incident cancer had been diagnosed in 11.2% of 2196 statin-naïve individuals (mean age 50.5 years, 55% women) from the offspring and third-generation cohorts of the community-based longitudinal Framingham Heart Study.

The risk for cancer was a significant 80% higher among the 812 statin-eligible participants, with an incidence of 15.4%, than among the 1384 noneligible participants, at 8.8%.

Individuals eligible for statins, the guidelines for which are mainly based on a composite cardiovascular risk profile, rather than cholesterol level thresholds, also had a significant 12.1-fold increased risk for cancer mortality (4.2 vs 0.4%) and a 10.1-fold increased risk for noncardiovascular mortality (6.0 vs 0.7%) compared with those not eligible.

And when Pursnani and team stratified their data by age, body mass index, and smoking status, they observed similar results.

This "suggests that the association of cardiovascular risk with noncardiovascular outcomes is not driven by any one common causative risk factor in both cancer and [cardiovascular disease], but rather by the complex interplay of the several risk components that form the basis for determining statin eligibility, including age, blood pressure, cholesterol, smoking status, and diabetes," they write in the Journal of Clinical Oncology.

The researchers add: "The most important conclusion of our data is that there is an opportunity to improve public health awareness of shared risk factors for cardiovascular and cancer outcomes.

"If statin eligibility is, as our data suggest, not only an indicator of a higher risk of [atherosclerotic cardiovascular disease] but also of cancer incidence and mortality, the ACC/AHA guidelines present a unique and simple platform for identifying a cohort that is at a higher risk of cancer and cancer-related death," they conclude.

Original article appeared in 07-28-2017 | Oncology | News | Article.


3. Useful Links

Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

  

 

4. Calcium Absorption Test

EZorb Calcium has set a new world record of absorption rate. You can compare EZorb with other calcium supplements by using the simple step-by-step instructions we provide. E-mail your request to test @ elixirindustry.com for a copy of the instructions.

 

 

5. What Are Others Saying About EZorb and Marvlix?

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

 

Back to EZorb Newsletter Index

 
  Copyright 2018 Elixir Industry